A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis-Reference-Cited by-同舟云学术

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Published:2012-06-20 Issue:8 Volume:62 Page:1122-1130
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Rutgeerts Paul J,Fedorak Richard N,Hommes Daan W,Sturm Andreas,Baumgart Daniel C,Bressler Brian,Schreiber Stefan,Mansfield John C,Williams Marna,Tang Meina,Visich Jennifer,Wei Xiaohui,Keir Mary,Luca Diana,Danilenko Dimitri,Egen Jackson,O'Byrne Sharon

Publisher

BMJ

Subject

Gastroenterology

Reference51 articles.

1. Inflammatory bowel disease: clinical aspects and established and evolving therapies;Baumgart;Lancet,2007

2. Toxic megacolon;Autenrieth;Inflamm Bowel Dis

3. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial;Hanauer;Lancet,2002

4. Natalizumab induction and maintenance therapy for Crohn's disease;Sandborn;N Engl J Med,2005

5. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis;Van Assche;Gastroenterology,2003

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of low volume sampling devices for a pharmacodynamic biomarker analysis: Challenges and solutions;Journal of Pharmaceutical and Biomedical Analysis;2024-12

2. Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis;PeerJ;2024-08-23

3. Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta‐analysis;Health Science Reports;2024-05

4. Meta-analysis of etrolizumab versus placebo in ulcerative colitis: safety and efficacy outcomes;Therapeutic Advances in Gastroenterology;2024-01

5. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis: a protocol of systematic review and meta-analysis of placebo-controlled, randomised clinical trials;BMJ Open;2024-01